Literature DB >> 19484391

Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine.

Dalila Belhani1, Laurent Fanton, Fanny Vaillant, Jacques Descotes, Waheed Manati, Alain Tabib, Bernard Bui-Xuan, Quadiri Timour.   

Abstract

Further to our previous observation of post-mortem cardiac lesions after sudden death in several athletes with a history of anabolic steroid abuse, this study was intended to reproduce these lesions in rabbits administered testosterone oenanthate, a prototypic anabolic steroid abused by athletes, and to provide evidence for the protective effects of trimetazidine and dexrazoxane that are used as antianginal and cardioprotective drugs, respectively. Groups of six rabbits each were administered saline, testosterone, or a combination of testosterone and either trimetazidine or dexrazoxane for 3 months. Histologic cardiac lesions including necrosis, misshapen cell nuclei, interstitial and endocardial fibrosis, lymphocytic infiltrates, and vascular dystrophies were observed in testosterone-treated rabbits. In contrast, no significant lesions were observed in the animals treated with testosterone combined with either trimetazidine or dexrazoxane. This is the first study providing evidence for testosterone cardiotoxicity following sub-chronic exposure in laboratory animals. In addition, these results suggest the protective role of trimetazidine and dexrazoxane.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484391     DOI: 10.1007/s12012-009-9041-7

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  4 in total

1.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

Review 2.  Anabolic steroids and cardiovascular risk.

Authors:  Peter Angell; Neil Chester; Danny Green; John Somauroo; Greg Whyte; Keith George
Journal:  Sports Med       Date:  2012-02-01       Impact factor: 11.136

3.  Effect of exercise training and anabolic androgenic steroids on hemodynamics, glycogen content, angiogenesis and apoptosis of cardiac muscle in adult male rats.

Authors:  Asmaa F Hassan; Manal M Kamal
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

4.  Cardiovascular effects in childhood cancer survivors treated with anthracyclines.

Authors:  Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Cardiol Res Pract       Date:  2011-02-10       Impact factor: 1.866

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.